DMD Simcyp

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Otake, Y.
Right arrow Articles by Walle, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Otake, Y.
Right arrow Articles by Walle, T.

Vol. 30, Issue 2, 103-105, February 2002

SHORT COMMUNICATION
Oxidation of the Flavonoids Galangin and Kaempferide by Human Liver Microsomes and CYP1A1, CYP1A2, and CYP2C9

Yoko Otake and Thomas Walle

Department of Cell and Molecular Pharmacology
and Experimental Therapeutics,
Medical University of South Carolina,
Charleston, South Carolina

There is very limited information on cytochrome P450 (P450)-mediated oxidative metabolism of dietary flavonoids in humans. In this study, we used human liver microsomes and recombinant P450 isoforms to examine the metabolism of two flavonols, galangin and kaempferide, and one flavone, chrysin. Both galangin and kaempferide, but not chrysin, were oxidized by human liver microsomes to kaempferol, with Km values of 9.5 and 17.8 µM, respectively. These oxidations were catalyzed mainly by CYP1A2 but also by CYP2C9. Consistent with these observations, the human liver microsomal metabolism of galangin and kaempferide were inhibited by the P450 inhibitors furafylline and sulfaphenazole. In addition, CYP1A1, although less efficient, was also able to oxidize the two flavonols. Thus, dietary flavonols are likely to undergo oxidative metabolism mainly in the liver but also extrahepatically.

Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Am. J. Clin. Nutr.Home page
J. W Lampe
Interindividual differences in response to plant-based diets: implications for cancer risk
Am. J. Clinical Nutrition, May 1, 2009; 89(5): 1553S - 1557S.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
U. K. Walle and T. Walle
Bioavailable Flavonoids: Cytochrome P450-Mediated Metabolism of Methoxyflavones
Drug Metab. Dispos., November 1, 2007; 35(11): 1985 - 1989.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
C. Chen, L. Meng, X. Ma, K. W. Krausz, Y. Pommier, J. R. Idle, and F. J. Gonzalez
Urinary Metabolite Profiling Reveals CYP1A2-Mediated Metabolism of NSC686288 (Aminoflavone)
J. Pharmacol. Exp. Ther., September 1, 2006; 318(3): 1330 - 1342.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
D. Nikolic and R. B. van Breemen
NEW METABOLIC PATHWAYS FOR FLAVANONES CATALYZED BY RAT LIVER MICROSOMES
Drug Metab. Dispos., April 1, 2004; 32(4): 387 - 397.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
Y. Otake, F. Hsieh, and T. Walle
Glucuronidation versus Oxidation of the Flavonoid Galangin by Human Liver Microsomes and Hepatocytes
Drug Metab. Dispos., May 1, 2002; 30(5): 576 - 581.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics.